Biologics Safety Testing Market worth $6.8 billion by 2027 | Growth, Opportunities Business Scenario, Share, Scope, Key Segments and Forecast
global biologics safety testing market is driven by factors such as companies investing heavily in the development of biologics and biosimilars, strict regulatory concerns over growing cell culture contamination, and increased demand for various drugs, cell therapies, diagnostics, and active biological products.
Biologics Safety Testing Market is projected to reach USD 6.8 billion by 2027 from USD 3.6 billion in 2022, at a CAGR of 13.3% during the forecast period according to a new report by MarketsandMarkets™. The growth of the global biologics safety testing market is driven by factors such as companies investing heavily in the development of biologics and biosimilars, strict regulatory concerns over growing cell culture contamination, and increased demand for various drugs, cell therapies, diagnostics, and active biological products.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144
Browse in-depth TOC on “Biologics Safety Testing Market”
185 – Tables
46 – Figures
249 – Pages
Key Market Players
Prominent players in the biologics safety testing market are Charles River Laboratories, Inc. (US), Lonza (Switzerland), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Labcorp (US), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Sartorius AG (Germany), and Lonza (Switzerland). The key players in this market are focusing on strategic expansions, partnerships, and product & service launches and approvals to expand their presence in the market.
CHARLES RIVER LABRATORIES (US)
Charles River is one of the key players in the biologics safety testing market. It is a service and early-stage contract research organization (CRO). The company develops a diverse portfolio of discovery & safety assessment services by providing a suite of products and services to support its clients’ manufacturing activities. The company operates through three reporting segments, namely, Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The company offers biologics safety testing solutions through its Manufacturing Support segment. To further strengthen its market position, Charles River Laboratories focuses on expanding its service and product offerings in the biologics safety testing segment.
LONZA (SWITZERLAND)
Lonza is a key player in the biologics safety testing market. The company has a large number of manufacturing and R&D facilities worldwide. The company’s wide geographic presence and high production capacity deliver quality products worldwide. The company focuses on organic growth strategies to maintain its position in the biologics safety testing market.
THERMO FISCHER SCIENTIFIC (US)
Thermo Fisher Scientific offers analytical instruments, equipment, reagents, and consumables for research, discovery, analysis, diagnostics, and manufacturing. The company operates through four principal product segments—Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The company offers a wide array of biologics safety testing products through its Life Sciences Solutions segment.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=34624144
The Asia Pacific region is the fastest growing region of the Biologics safety testing market
The Asia Pacific market is projected to witness the highest growth rate during the forecast period. Rapid growth in outsourcing preclinical, clinical, and laboratory testing services to APAC countries is expected to drive market growth during the forecast period. Several companies are focusing on increasing their market shares and customer base in the region to capitalize on these opportunities in the Asia Pacific market.
Recent Developments:
- Merck KGaA (Germany) invested in expanding its biosafety testing capacity at Rockville, Maryland, US. This site will provide biosafety testing and analytical development services in the US.
- Eurofins Scientific (Luxembourg) acquired Wessling Hungary, a food, environmental, and BioPharma product testing laboratory in Hungary. This acquisition helped expand Eurofins’ biopharma testing business in Europe.
- Lonza (Switzerland) launched the PyroCell Monocyte Activation Test to detect non-endotoxin pyrogens and reduce interferences from complex drug products, such as biologics-based pharmaceuticals.
- Charles River Laboratories, Inc. (US) launched a new detection tool, EndoScan-V, a validated endotoxin detection and measurement software used to generate and report quantitative test data. The software performed the requisite measurements and calculations and created test reports with the convenience of digital signature report approval.
- Charles River Laboratories, Inc. (US) partnered with JADE Biomedical to expand its biological testing solutions capabilities geographically and cater to the increasing demand for biologics therapeutics, especially cell and gene therapies. This strategic relationship enabled JADE to expand its current global Good Manufacturing Practice (GMP) product testing operations in Shanghai into a second facility and further build upon its current offering of comprehensive biologics quality management and testing services.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=34624144
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/biologics-safety-testing-market-34624144.html
